No Increased Resistance With Once-Daily Dosing of Abacavir and 3TC Than Twice-Daily Dosing in the ARROW Trial
Once-daily dosing of abacavir (ABC) and lamivudine (3TC) was non-inferior to twice-daily dosing in development of viral resistance in the ARROW trial, according to data presented at the 8th International Workshop on HIV Pediatrics.
On behalf of IFARA, Fred Schaich spoke with Ann Chahroudi about the pediatric HIV cure research in infant rhesus macaques that was presented at this year's International AIDS Conference and why no single cure strategy will likely be effective.
For HIV-infected mothers whose immune system is in good health, taking a three-drug antiretroviral regimen during breastfeeding essentially eliminates HIV transmission by breast milk to their infants, according to results from a large clinical trial ...
A report from the PROMISE study showed no adverse bone mineral effect, linked to maternal tenofovir disoproxil fumarate (TDF), in exposed infants.
Physiologically based pharmacokinetic modeling can help predict dosing strategies for long-acting antiretrovirals, according to data presented at CROI 2016.
Population modelling and pharmacokinetic simulations shown at CROI 2016 predicted dosing regimens to achieve target nevirapine treatment concentrations in term and late preterm infants.
"I cried listening to Dr. Tonia Poteat's CROI 2016 plenary presentation in February, HIV in Transgender Populations: Charted and Uncharted Waters," writes Brandyn Gallagher. "A few times, actually."
Tonia Poteat, Ph.D., who delivered the first-ever plenary session focused on transgender people at CROI 2016, says it is unclear why the federal government cannot mandate inclusion of gender identity questions in the Behavioral Risk Factor Surveillan...
"There is probably no population that is both more heavily impacted [by HIV] and less discussed around the world than transgender people," said Susan Buchbinder, M.D., during a CROI 2016 presentation.
Dolutegravir is safe and effective in children age 6-12 years, according to results presented at CROI 2016.